LUNA trial 2026: Spark Biomedical tests non-pharmacological device for heavy menstrual bleeding
Spark Biomedical launches LUNA Phase II trial evaluating wearable auricular neurostimulation for heavy menstrual bleeding. What the study design reveals.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
AptarGroup enters Phase II POSITS study as delivery partner for ENA Respiratory’s INNA-051 nasal spray
Aptar's UDS Powder system enters ENA Respiratory's POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.
Pharma & Biotech
What SPONTAN reveals about Aptar’s nasal drug delivery platform and the race for rapid acting erectile dysfunction treatments
Aptar’s nasal drug delivery system enters Phase II trial for LTR Pharma’s SPONTAN erectile dysfunction therapy. Discover what this means for intranasal medicines.
Pharma & Biotech
Alzamend Neuro moves AL001 into bipolar disorder patients as lithium reformulation race intensifies
Alzamend Neuro, the Nasdaq-listed clinical-stage biopharmaceutical company, has initiated a Phase II clinical trial of AL001, its ionic cocrystal lithium formulation, in patients diagnosed with bipolar disorder type 1, conducting the study at Massachusetts General Hospital in collaboration with Harvard Medical School investigators. The trial employs a crossover design in which participants receive both AL001